Invasive Candida species infections: A 5 year population-based assessment

Journal of Antimicrobial Chemotherapy

Volumn 56, Issue 3, 2005, Pages 532-537

  Laupland, Kevin B ^a,b   Gregson, Daniel B ^a,b,c   Church, Deirdre L ^a,b,c   Ross, Terry ^b   Elsayed, Sameer ^a,b,c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c CALGARY LABORATORY SERVICES   (Canada)

Author keywords

Candidaemia; Mortality; Susceptibility

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; VORICONAZOLE;

ADULT; AGE; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; CANADA; CANCER PATIENT; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDIASIS; CENTRAL NERVOUS SYSTEM INFECTION; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; FUNGUS ISOLATION; GEOGRAPHIC DISTRIBUTION; HEALTH SURVEY; HEMODIALYSIS; HIGH RISK POPULATION; HUMAN; INCIDENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; ORGAN TRANSPLANTATION; POPULATION RESEARCH; RISK ASSESSMENT; RISK FACTOR; SPECIES INVASION;

ANTIFUNGAL AGENTS; CANADA; CANDIDA; CANDIDIASIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MICROBIAL SENSITIVITY TESTS; NEOPLASMS; POPULATION SURVEILLANCE; RENAL DIALYSIS; RISK FACTORS; SURVIVAL RATE; TRANSPLANTS;

EID: 24644468147     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dki258     Document Type: Article

References (42)

1. Gudlaugsson O, Gillespie S, Lee K et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-7.
2. Hobson RP. The global epidemiology of invasive Candida infections - is the tide turning? J Hosp Infect 2003; 55: 159-68.
3. Laupland KB, Zygun DA, Davies HD et al. Population-based assessment of intensive care unit-acquired bloodstream infections in adults: Incidence, risk factors, and associated mortality rate. Crit Care Med 2002; 30: 2462-7.
4. Laupland K, Kirkpatrick A, Church D et al. Intensive care unit-acquired bloodstream infections in a regional critically ill population. J Hosp Infect 2004; 58: 137-45.
5. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003; 3: 685-702.
6. Leleu G, Aegerter P, Guidet B. Systemic candidiasis in intensive care units: A multicenter, matched-cohort study. J Crit Care 2002; 17: 168-75.
7. Marchetti O, Bille J, Fluckiger U et al. Epidemiology of candidemia in Swiss tertiary care hospitals: Secular trends, 1991-2000. Clin Infect Dis 2004; 38: 311-20.
8. Clark TA, Hajjeh RA. Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis 2002; 15: 569-74.
9. Wong-Beringer A, Kriengkauykiat J. Systemic antifungal therapy: New options, new challenges. Pharmacotherapy 2003; 23: 1441-62.
10. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. New Engl J Med 2002; 347: 2020-9.
11. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142-51.
12. Ullmann AJ. Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole. Curr Med Res Opin 2003; 19: 263-71.
13. Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. New Engl J Med 2002; 346 225-34.
14. Rees JR, Pinner RW, Hajjeh RA et al. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of population-based laboratory active surveillance. Clin Infect Dis 1998; 27: 1138-47.
15. Kao AS, Brandt ME, Pruitt WR et al. The epidemiology of candidemia in two United States cities: Results of a population-based active surveillance. Clin Infect Dis 1999; 29: 1164-70.
16. Hajjeh RA, Sofair AN, Harrison LH et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004; 42: 1519-27.
17. Diekema DJ, Messer SA, Brueggemann AB et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 2002; 40 1298-302.
18. Tortorano AM, Biraghi E, Astolfi A et al. European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: Report from one Italian region. J Hosp Infect 2002; 51: 297-304.
19. Poikonen E, Lyytikainen O, Anttila VJ et al. Candidemia in Finland, 1995-1999. Emerg Infect Dis 2003; 9: 985-90.
20. Cuenca-Estrella M, Rodriguez D, Almirante B et al. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: Results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Chemother 2005; 55:194-9.
21. Davies HD, McGeer A, Schwartz B et al. Invasive group A streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group. New Engl J Med 1996; 335: 547-54.
22. Pitout JD, Hanson ND, Church DL et al. Population-based laboratory surveillance for Escherichia coli-producing extended-spectrum β-lactamases: Importance of community isolates with blaCTX-M genes. Clin Infect Dis 2004; 38: 1736-41.
23. Farley MM, Harvey RC, Stull T et al. A population-based assessment of invasive disease due to group B Streptococcus in nonpregnant adults. New Engl J Med 1993; 328: 1807-11.
24. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard M27-A2, 2nd edn. NCCLS, Villanova, PA, USA, 2002.
25. Odds FC, Motyl M, Andrade R et al. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol 2004; 42: 3475-82.
26. Laupland KB, Gregson DB, Zygun DA et al. Severe bloodstream infections: A population-based assessment. Crit Care Med 2004; 32: 992-7.
27. Laupland KB, Church DL, Mucenski M et al. Population-based study of the epidemiology of and the risk factors for invasive Staphylococcus aureus infections. J Infect Dis 2003; 187: 1452-9.
28. Laupland KB, Davies HD, Low DE et al. Invasive group A streptococcal disease in children and association with varicella-zoster virus infection. Ontario Group A Streptococcal Study Group. Pediatrics 2000; 105: E60.
29. Mao Y, Morrison H, Semenciw R et al. The prevalence of cancer in Canada. Can J Public Health 1991; 82: 61-2.
30. Center for Chronic Disease Prevention and Control. Diabetes in Canada, Second Edition. Population and Public Health Branch, Health Canada, Ottawa, Canada, 2002.
31. Coresh J, Astor BC, Greene T et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41: 1-12.
32. Manns B, Mortis G, Taub K et al. The Southern Alberta Renal Program database: A prototype for patient management and research initiatives. Clin Invest Med 2001; 24: 164-70.
33. Federal, Provincial, and Territorial Advisory Committee on Population Health. Statistical Report on the Health of Canadians. Ottawa, ON, Canada: Health Canada, 1999.
34. Lawrence RC, Hochberg MC, Kelsey JL et al. Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States. J Rheumatol 1989; 16: 427-41.
35. Laupland K. Population-based epidemiology of intensive care: Critical importance of ascertainment of residency status. Crit Care 2004; 8: R431-436.
36. Pastor P, Medley FB, Murphy TV. Meningococcal disease in Dallas County, Texas: Results of a six-year population-based study. Pediatr Infect Dis J 2000; 19: 324-8.
37. Piscopo T, Mallia-Azzopordi C, Grech V et al. Epidemiology and prognostic factors in meningococcal disease in a small island population: Malta 1994-1998. Eur J Epidemiol 2000; 16: 1051-6.
38. Garbino J, Kolarova L, Rohner P et al. Secular trends of candidemia over 12 years in adult patients at a tertiary care hospital. Medicine (Baltimore) 2002; 81: 425-33.
39. Fraser VJ, Jones M, Dunkel J et al. Candidemia in a tertiary care hospital: Epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992; 15: 414-21.
40. Bukharie HA. Nosocomial candidemia in a tertiary care hospital in Saudi Arabia. Mycopathologia 2002; 153: 195-8.
41. Rennert G, Rennert HS, Pitlik S et al. Epidemiology of candidemia - a nationwide survey in Israel. Infection 2000; 28: 26-9.
42. Karlowsky JA, Zhanel GG, Klym KA et al. Candidemia in a Canadian tertiary care hospital from 1976 to 1996. Diagn Microbiol Infect Dis 1997; 29: 5-9.